Overview: MGMT TestIntroduction: The MGMT Test detects MGMT methylation to assess brain tumor treatment response, aiding prognosis. Aligned with 2023 NCCN guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding treatment planning, predicting prognosis, and improving outcomes in molecular pathology for patients with suspected gliomas or brain tumors.
Other Names: MGMT Methylation Assay, Brain Tumor Methylation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MGMT methylation testing began in the 2000s with glioma research. PCR methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects MGMT methylation to assess brain tumor treatment response, guides therapy, and evaluates prognosis.
Test Parameters: 1. MGMT Methylation
Pretest Condition: No fasting required. Collect tissue. Report history of neurological symptoms or brain tumor diagnosis.
Specimen: Tissue (FFPE, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document neurological symptoms, seizures, or history of brain tumor. Include current medications, especially chemotherapy or radiation.
Consent: Written consent required, detailing the tests purpose, brain tumor implications, and risks of biopsy.
Procedural Considerations: Uses PCR to detect MGMT methylation in tissue. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for glioma prognosis.
Factors Affecting Result Accuracy: Low DNA yield or improper tissue fixation can affect results. Contamination may reduce specificity.
Clinical Significance: MGMT methylation predicts better response to alkylating agents (e.g., temozolomide), guiding therapy. Unmethylated MGMT suggests poorer prognosis.
Specialist Consultation: Consult an oncologist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, IDH mutation testing, or 1p/19q deletion testing to confirm brain tumor diagnosis.
Test Limitations: Limited to specific tumor types; clinical correlation is needed. Sample quality affects sensitivity.
References: NCCN Brain Tumor Guidelines, 2023; Neuro-Oncology, Hegi ME, 2022.
